Journal profile · RHEUMATOLOGY
Current Treatment Options in Rheumatology
ISSN 2198-6002
Current Treatment Options in Rheumatology: CAS Zone 4 · Medicine (2025 upgraded edition); hybrid open access; APC about USD 3,990; 20 articles in 2025; flagged on an early-warning list or for an indexing change: check before submitting; the journal's website says submissions are paused or closed.
The journal's website says submissions are paused or closed: Current Treatment Options in Rheumatology is now archived and no longer receiving submissions with this publisher. All articles published in the journal during its time with Springer will remain fully searchable through our websites. Source ↗Publisher website ·
Scope
Aims, scope and focus
Current Treatment Options in Rheumatology is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Systemic Sclerosis and Related Diseases, Rheumatoid Arthritis Research and Therapies and Vasculitis and related conditions, together about 29.9% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): RHEUMATOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Systemic Sclerosis and Related DiseasesMedicine13.7%
- Rheumatoid Arthritis Research and TherapiesMedicine8.4%
- Vasculitis and related conditionsMedicine7.8%
- Systemic Lupus Erythematosus ResearchMedicine7.6%
- Inflammatory Myopathies and DermatomyositisMedicine6.8%
- Myasthenia Gravis and ThymomaMedicine5.1%
- Musculoskeletal pain and rehabilitationMedicine4.5%
- Autoimmune and Inflammatory Disorders ResearchMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Rheumatology | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
Early warning / risk: Marked as ceased in ESCI on 16 February 2026. CAS Early Warning Journal List: not listed in any of 6 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 25OpenAlex ·
- i10-index
- 65OpenAlex ·
- 2-year mean citedness
- 2OpenAlex ·
- Share of gold OA articles
- 25%LetPub ·
Volume
- Articles per year
- 7LetPub ·
Articles by year OpenAlex count · 238 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 262 |
| 2025 | 20 | 10 | 339 |
| 2024 | 7 | 2 | 349 |
| 2023 | 15 | 9 | 276 |
| 2022 | 10 | 6 | 281 |
| 2021 | 22 | 11 | 313 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
Too few articlesOnly 5 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,990 / EUR 2,990 / GBP 2,590 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright
- License & copyright
The journal is archived and no longer accepting submissions with this publisher. Model summary
Current Treatment Options in Rheumatology is now archived and no longer receiving submissions with this publisher.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- ISSN
- 2198-6002
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Current Treatment Options in Rheumatology
What CAS zone is Current Treatment Options in Rheumatology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Treatment Options in Rheumatology is in Zone 4 of Medicine, and in Zone 4 of the minor category Rheumatology. Zones from different editions, and from major and minor categories, are not interchangeable.
Is Current Treatment Options in Rheumatology open access, and what is the APC?
Current Treatment Options in Rheumatology is a hybrid journal. For open-access publication: APC about USD 3,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .